Microbot Medical Reports Over 100% Q2 Revenue & Customer Growth, Expands Sales & Manufacturing
MBOT sits 21% above its 52-week low of $1.6 on light trading volume (0.3× avg).
Summary
Microbot Medical announced over 100% growth in Q2 revenue and new customers for its LIBERTY Endovascular Robotic System, alongside expanded sales territories and manufacturing capabilities.
Key Events · Product Development and Regulatory · MBOT
-
Strong Q2 Commercial Growth
Reported greater than 100% growth in revenue and new customers for the second quarter ended June 30, 2026, compared to the first quarter.
-
Expanded Market Adoption
The LIBERTY System was adopted by leading health systems in Massachusetts, North Carolina, Michigan, and Pennsylvania following its full market release in April.
-
Federal Market Penetration
Entered an agreement with Lovell Government Services Inc. to sell to federal healthcare systems, including the Veterans Health Administration and Military Health System.
-
Increased Sales Footprint & Manufacturing
Broadened U.S. sales territories from 4 to 8 in Q2, targeting 12 by year-end, and established a second manufacturing site to meet demand.
Analysis · MBOT · Industrial Applications And Services
Microbot Medical reported significant commercial success for its LIBERTY Endovascular Robotic System, with revenue and new customers more than doubling in Q2 2026 compared to Q1. This strong growth validates the company's full market release strategy and indicates increasing adoption of its robotic system. The expansion of sales territories, securing federal contracts, and establishing a second manufacturing site position the company for continued growth and improved capacity to meet rising demand.
At the time of this filing, MBOT was trading at $1.94 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $129.6M. The 52-week trading range was $1.60 to $4.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.